Latest News and Press Releases

Hamilton, March 07, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a...

Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical...

Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%Creation of dedicated...